Introduction
Phosphonates, i.e., compounds having a C-P bond, are found in archaea, bacteria and eukaryotes and it has been suggested that they are important intermediates in the global phosphorus cycle. 1, 2 The relative stability of the C-P bond makes phosphonolipids and phosphonoglycans less susceptible to enzymatic hydrolysis than phosphates, thereby providing a selective advantage in phosphate-limited environments. 2 As phosphonates are structurally similar to phosphate esters and carboxylates, that same stability can also contribute to biological activity, with antibacterial, antiviral, antiparasitic and herbicidal activity all having been attributed to phosphonates. 1, 3 As shown in Scheme 1, there are two enzymes that are common to the biosynthesis of virtually all biogenic phosphonates. 4, 5 The first, PEP mutase, catalyzes the conversion of phosphoenolpyruvate (PEP, 1) to phosphonopyruvate (PnP, 2). This reaction is thermodynamically unfavorable 6 so a second enzyme, phosphonopyruvate decarboxylase (PnPDC), is used to introduce an irreversible step. 7 Phosphonoacetaldehyde (PnAA, 3), the 4 product of the decarboxylation reaction, is subsequently converted to a variety of phosphonic acid natural products.
Some of these products have found therapeutic use. Fosfomycin, a broad-spectrum antibiotic, is used in the treatment of cystitis. 8 Plumbemycin 5 and dehydrophos 9 also act as antibiotics while phosphinothricin, as its tripeptide with two alanine residues (bialaphos), is a natural herbicide. 10 2-Aminoethylphosphonate (2-AEP) is used by microorganisms in a variety of ways. For many, it provides a source of useable carbon, nitrogen and phosphorus. 11 For others, 2-AEP provides a counterpart to the lipid polar head group, phosphoethanolamine, that is resistant to chemical and enzymatic hydrolysis. 12 Still others use it in the synthesis of bioactive compounds such as argolaphos, a broad-spectrum antibacterial phosphonopeptide. 13 It is also notable that several well-known mammalian and plant pathogens produce phosphonates. Fosfomycin, for example, although it does have a therapeutic use, is produced by Pseudomonas syringae, a plant pathogen which infects fruit-bearing trees.
14 Naegleria fowleri, known colloquially as the "brain-eating amoeba", causes meningoencephalitis in humans, and has been shown to produce phosphonates. 15 In Bacteroides fragilis, a human pathogen involved in abscess formation, a 2-AEP-containing capsular polysaccharide has been identified as the major virulence factor, 12 while the genes for 2-AEP biosynthesis have been identified in Trypanosoma cruzi, the causative agent of Chagas' disease. 16 Since phosphonate metabolism is not present in humans or higher plants/animals, it offers a promising target for drug design against these phosphonate producing and using pathogens.
Intriguingly, the antibiotic action of dehydrophos provides a clue as to how this problem may be approached. Dehydrophos acts as a "Trojan horse" in that is taken into the cell by peptide permeases, whereupon it is activated by intracellular proteases to unmask methyl 21, 22 However, in this instance, addition of ThDP to fluoropyruvate is followed by decarboxylation, generating a carbanion and leading to elimination of fluoride. The resulting vinyl alcohol tautomerizes to give acetyl-ThDP which likely reacts with a nucleophile in the active site thereby inactivating the enzyme. 21, 22 Given that phosphonopyruvate decarboxylase, which catalyzes the irreversible step in phosphonate biosynthesis, 7 is also a ThDP-dependent decarboxylase, it would appear to be an ideal target for similar mechanism-based inhibitors. One such compound, shown in Scheme 2, is 3-phosphono-3,3-difluoropyruvate (PnDFP, 4) an analogue of the natural substrate, phosphonopyruvate (3). It is expected that PnDFP will be accepted by the enzyme and react with the ThDP ylid to provide intermediate (5) . However, following decarboxylation, the resulting carbanion (6) will eliminate fluoride to produce an inactive enol-ThDP complex (7) . Potentially this could tautomerize to yield an phosphonofluoroacetyl-ThDP complex (8) but, regardless, the enzyme will remain inactivated.
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In this paper we describe the synthesis and testing of 4 with the PnPDC from Bacteroides fragilis (BfPnPDC). PnDFP proved to be a potent inhibitor of the enzyme, and showed all the characteristics of a mechanism-based inhibitor.
Results

Synthesis of 3-phosphono-3,3-difluoropyruvate (PnDFP, 4)
PnDFP (4) could be obtained in three steps from diethyl difluoromethylphosphonate (9) by deprotonation with freshly prepared lithium diisopropylamide (LDA) at −78 °C (Scheme 3). The resulting difluoromethyllithium could be reacted with diethyl oxalate ((CO 2 Et) 2 ), followed by acidic work up to give the desired product in its hydrate form (10a) in 60% yield. The hydrate 10a can be partly converted to the ketone (10b) by bulb-to-bulb distillation (ratio 10a:10b after distillation = 1:1.1).
The final deprotection was a two-step process. First, the phosphonic acid moiety was deprotected using TMSBr/allylTMS for 24 h at 60 °C. The relatively high temperature and long reaction time were necessary due to the large electron withdrawing effect of the CF 2 group. Next, the ester was saponified at pH > 10 in aqueous NaOH, and the final product passed through Dowex 50Wx8, H + form, in order to remove excess base. The pH was adjusted to 7 using aqueous NaOH and the sodium salt of 4 was isolated by lyophilisation as a colorless powder.
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Expression, purification and kinetic characterization of BfPnPDC
The expression and purification of the C-terminal His-tagged BfPnPDC proceeded smoothly and in good yield. The steady state kinetics of BfPnPDC were determined using a modified coupled assay. 12, 23 In a typical assay for a pyruvate decarboxylase (PDC), the coupling enzyme is a yeast alcohol dehydrogenase (YADH) , that catalyzes the reduction of acetaldehyde and the concomitant oxidation of NADH, thus allowing the reaction to be followed spectrophotometrically at 340 nm. Phosphonoacetaldehyde (3), the product of the BfPnPDC reaction, is not a substrate for YADH. However, the phosphono group can be removed by phosphonoacetaldehyde hydrolase (Phtase) which then allows further reaction with YADH.
Accordingly, the Phtase from P. putida was also expressed and affinity purified. Its utility in the coupled assay was verified using authentic phosphonoacetaldehyde and YADH. 27 It has been suggested that much of the difference in catalytic efficiency results from the presence of the "phosphono" group which is the major source of enzyme-substrate binding energy. 9
Reaction of PnDFP with BfPnPDC
In control experiments the inhibitor was tested against both Phtase and YADH. 
PnDFP irreversibly inactivates BfPnPDC
To determine if the inhibition was (i) time-dependent and (ii) irreversible, a dilution study was performed. A mixture of enzyme (6 M) and 4 (50 M) was incubated at 30 °C before an aliquot was diluted 1:100 into an assay mixture containing saturating PnP. No activity was observed at
any of the time points tested. Reducing the inhibitor concentration to 10 M gave similar results.
Further, no enzyme activity was recovered after overnight dialysis. Taken together this indicates that the inhibitor binds both rapidly and, in effect, irreversibly.
Titration of BfPnPDC with PnDFP monitored by UV-Vis spectroscopy.
The first step in the reaction of ThDP-dependent enzymes is generally the formation of a covalent nucleophilic adduct between the C2 atom of the thiazolium ring of ThDP and the carbonyl group of the substrate. 28 The reaction continues via a series of covalently bound ThDPcomplexes, many of which can be observed by both UV spectrophotometry and circular dichroism (CD) spectrosopy. 29 Assuming PnDFP is a mechanism-based inhibitor of BfPnPDC (Scheme 2), it may be expected that titration of the inhibitor would provide a "signature" UV or CD signal. This proved to be true as the addition of PnDFP to the enzyme resulted in a yellow color. Bradford measurements. The latter is not unexpected as variation in concentrations arising from the Bradford method are common. 30 Unfortunately, interference due to the presence of ThDP in the storage buffers renders OD 280 measurements even less reliable.
Titration of BfPnPDC with PnDFP monitored by CD spectropolarimetry.
CD was also used to monitor a similar titration of BfPnPDC with 4, with results shown in Figure 2 . Two maxima were observed. The first, around 315 nm, has been attributed to formation of the 1',4'-iminopyrimidine tautomer of enzyme-bound ThDP 29, 31 or intermediates related to C2-adducts of ThDP. [32] [33] [34] The second maximum, around 440 nm, has been attributed to formation of a charge transfer band, likely arising from an interaction of a  bond on the C2 sidechain of ThDP and the positively charged thiazolium ring as donor and acceptor, respectively. 29 As with the UV data, the CD data at 440 nm showed a linear increase with inhibitor concentration, again with a plateau around 35 M inhibitor ( Figure S1 ). 
Reaction of PnDFP with BfPnPDC releases fluoride ion.
The postulated mechanism for the reaction of PnDFP with the ThDP of BfPnPDC (Scheme 2)
requires the elimination of a fluoride ion. To test this hypothesis, a fluoride ion-selective probe was used to analyze the products of the titration of the enzyme (~100 µM) with PnDFP (100 mM). 
Screening for crystals of BfPnPDC
Attempts were made to crystallize BfPnPDC in the presence and absence of 4. All attempts were unsuccessful.
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Discussion
Biosynthesis of phosphonates is important to many pathogenic organisms. 12, [14] [15] [16] Given that they are not produced in higher plants, animals and humans, it seemed as though the phosphonate biosynthetic pathway would be worth exploring as a target for novel antibiotics. An important consideration is that two enzymes, PEP mutase and PnPDC, catalyze the first two steps in the biosynthesis of virtually all known phosphonates (Scheme 1). Accordingly, by focusing on these enzymes it is possible to envisage a general strategy to interfere with all phosphonate biosynthesis. PnPDC was chosen as our initial target as it (i) carries out an irreversible biosynthetic step and (ii) is of fundamental interest in that it is thought to closely resemble the fused domain common ancestor of all ThDP-dependent enzymes. 35, 36 To date, only two PnPDCs, those from Bacteroides fragilis (BfPnPDC) 12 and Streptomyces viridochromogenes Tü494 (SvPnPDC) 23 have been fully characterized. The former is from a human pathogen while the latter organism produces the natural herbicide bialaphos and the antibiotic, streptazolin.
Another PnPDC, that from Streptomyces hygroscopicus, has been purified but not well characterized. 37 Confusingly, gel filtration analysis has suggested that the native enzymes existed as a homotrimer, a homodimer and a homotetramer, respectively. The oligomeric status could be clarified by an X-ray structure but, as yet, no PnPDC has been crystallized. It was hoped that formation of an inhibitor:ThDP adduct may facilitate crystallization, as has been observed for other ThDP enzymes such as benzoylformate decarboxylase 33, 38 and benzaldehyde lyase. 39, 40 In the first instance we proposed that 3,3-difluoro-3-phosphonopyruvate (PnDFP, 4) would act specifically as mechanism-based inhibitor for PnPDC. To explore this possibility the sodium salt of PnDFP was synthesized in three steps from diethyl difluoromethylphosphonate (Scheme 3).
An alternative strategy employing dibromodifluoromethane as the starting material [41] [42] [43] [44] [45] was also successful, although the yields were much more variable. Concomitantly we were able to express and purify BfPnPDC as a C-terminal his-tagged variant, and used a coupled assay to confirm that its kinetic data were identical to that of the wild type enzyme. Testing showed that 4 was a potent inhibitor of BfPnPDC, with a K i value in the sub-micromolar range.
Silverman 46 has defined several criteria, most of which should be met by 4, in order for it to be characterized as a mechanism-based inhibitor. These include (a) time-dependent inactivation, (ii) saturation kinetics, (iii) substrate protection, (iv) irreversible inactivation, (v) 1:1 stoichiometry of binding, (vi) involvement of a catalytic step and (vii) that binding occurs at the active site.
PnDFP is clearly an analogue of the substrate, PnP, and shows the qualities necessary to call it a mechanism-based inhibitor. Indeed, its reaction with BfPnPDC was sufficiently rapid to preclude the dilution assay normally used to demonstrate that time-dependent inactivation was accompanied by saturation kinetics. Nonetheless we could show that inactivation could not be Perhaps the most important criterion for a mechanism-based inhibitor is the involvement of a catalytic step. For 4 we were able to confirm this by using an ion-selective electrode to establish that enzyme inactivation was accompanied by the release of a fluoride ion. Figure 3 shows that,
when BfPnPDC was titrated with 4, there was a 1:1 relationship between the concentration of free F -and added inhibitor. Taken together, all data point to PnDFP being a potent mechanismbased inhibitor of phosphonopyruvate decarboxylase. At this time it is not clear which ThDP complex (7 or 8, Scheme 2) is responsible for the inhibition, and analogues of both keto and enol complexes have been reported on ThDP-dependent enzymes. 29 It is notable that 8 is an analogue of acetylthiamin diphosphate which may expected to be hydrolyzed. Two observations mitigate against this. First, there is no rapid loss of the absorbance at 440 nm and second, there is no rapid regeneration of active enzyme. It appears that, while acylthiamin diphosphate intermediates can hydrolyze rapidly on some enzymes, on others, such as pyruvate oxidase 48 and benzoylformate decarboxylase 49 , it can be quite slow. PnPDC would seem to fit into the latter category. Another possibility is that the equilibrium lies in favor of 8, which is subsequently attacked by an active site nucleophile. Such a mechanism was proposed for the inactivation of the E1 subunit of the pyruvate dehydrogenase complex. 22 It was hoped that this issue could be resolved by crystallography but, unfortunately, X-ray quality crystals are not yet available. Screening for suitable conditions is continuing.
While inhibition of PnPDC is the prime focus of this paper, it must be remembered that PnP is also a substrate of PEP mutase (Scheme 1). There remains the possibility that 4 could be converted into difluoroPEP and, given that monofluoroPEP inhibits several PEP utilizing enzymes, 50 there is a good chance that difluoroPEP would behave similarly. Even assuming that 16 difluoroPEP acts as a substrate for the PEP enzymes, subsequent transformations would result in the formation of fluorinated pyruvate analogs which are also toxic. It is also important to note that PEP mutase is not found in higher organisms and, therefore, no fluorinated PEP or subsequent products will be formed in mammalian cells. Given this, and the success of 4 as a PnPDC inhibitor, future work will focus on the development of 4 as an in vivo inhibitor of phosphonate biosynthesis. (85%) (δ P 0.00) and FCCl 3 (δ F 0.00). Chemical shifts (δ) are given in ppm and coupling constants (J) in Hz. IR spectra were recorded on a Bruker VERTEX 70 IR spectrometer in ATR mode.
Experimental section
General methods
Spectra for compounds 4 and 10a are provided as supplementary material.
TLC was usually carried out on 0.25 mm thick Merck plates precoated with silica gel 60 F 254 .
Spots were visualised by UV and/or dipping the plate into a solution of (NH 4 ) 6 Mo 7 O 24 ·4H 2 O (25.0 g) and Ce(SO 4 ) 2 ·4H 2 O (1.0 g) in 10% aqueous H 2 SO 4 (500 mL), followed by heating with a heat gun. Flash (column) chromatography was performed with Merck silica gel 60 (230-400 mesh).
Diethyl difluoromethylphosphonate, bromotrimethylsilane, allyltrimethylsilane and diethyl oxalate were from Sigma Aldrich. THF was refluxed over potassium and distilled prior to use.
Authentic samples of PnP (2) and PnAA (3) were prepared as their sodium salts using variations on established methods. Details are provided in the supplementary material. All other chemicals and buffer components were used as purchased from Sigma-Aldrich, Acros, Fluka or Merck. Following transformation of the plasmids, pET24bBfPnPDC-His and pET22Phtase-His into E.
Ethyl 3-(diethoxyphosphoryl)
coli BL21(DE3) cells, expression and purification of the enzymes was achieved using routine procedures. 52 The enzymes were quantitated with the Bradford method 53 using bovine serum albumin as the standard before being concentrated to ~15 mg/mL. BfPnPDC was stored at -80 °C and Phtase was stored at 4 °C in 50 mM HEPES (pH 8.0) containing 300 mM NaCl, 10 mM MgCl 2 , and 1 mM DTT.
Steady-state kinetic analysis of phosphonopyruvate decarboxylase
The activity of purified BfPnPDC was determined using a coupled assay. The assay mixture contained, in a total of 1 mL, 100 mM HEPES (pH 7.0) 5 mM MgCl 2 , 0.2 mM NADH, 60 U/mL YADH, 100 μg phosphonoacetaldehyde hydrolase, and varying concentrations of phosphonopyruvate (0.5-15 µM). The reaction was carried out at 30 °C and initiated by the addition of BfPnPDC. Each assay was performed in triplicate. The kinetic parameters were determined by fitting the initial rate data to the Michaelis-Menten equation using the enzyme kinetics package from SigmaPlot 12.3.
Determination of IC 50 and K i values for difluorophosphonopyruvate
Here the standard assay was used with the concentration of phosphonopyruvate held constant at 3 µM (~K m ) or 30 µM (10×K m ) while the concentration of 4 was varied. The IC 50 value was determined by plotting the concentration of inhibitor (µM) against residual activity. The K i was determined from the IC 50 value using the Cheng-Prusoff equation (Equation 1).
Time-dependent inactivation of BfPnPDC
BfPnPDC (6 M) and 4 (10 M or 50 M) were mixed in 50 mM HEPES (pH 8.0) containing 300 mM NaCl, 10 mM MgCl 2 , and 1 mM DTT and incubated at 30 °C. At appropriate time intervals, an aliquot (10 L) was diluted 1:100 into a standard assay mixture containing 30 µM (i.e., saturating) phosphonopyruvate.
Reaction of phosphonodifluoropyruvate with BfPnPDC monitored by UV-VIS spectrophotometry and circular dichroism (CD) spectropolarimetry
BfPnPDC (~50 µM), in a 2 mL volume of BfPnPDC storage buffer, was titrated with 4 at concentrations ranging from 0-50 µM. PnDFP was introduced in 10 μL aliquots with each addition resulting in a 5 µM increase in inhibitor concentration. Spectra were obtained using a 1 cm path length cell. After the addition of each of the inhibitor aliquots, the solution was gently mixed and allowed to sit for a minimum of 3 minutes at 25 ˚C. The reaction mixtures were monitored on a Cary 50 Bio UV-Vis spectrophotometer at 440 nm to ensure the reaction was complete, before a scan was recorded from 550-250 nm. The Abs 440 titration curves were constructed using SigmaPlot 12.3.
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The procedure was repeated using the Jasco J-810 CD spectropolarimeter. The reaction was initially monitored at 440 nm on a UV-VIS spectrophotometer to ensure the reaction was complete. Subsequently the mixture was then scanned from 550-250 nm on the CD spectropolarimeter. The data obtained for each inhibitor concentration was the average of five individual scans. Titration curves for the change in ellipticity at 440 nm were constructed using SigmaPlot 12.3.
Fluoride ion analysis of the reaction of phosphonodifluoropyruvate with BfPnPDC
Release of fluoride ions from the reaction of 4 with BfPnPDC was monitored using a fluoride ion-selective electrode. Samples containing BfPnPDC (~100 µM) were mixed with PnDFP (0-75 µM) in a total volume of 1 mL. In addition, two controls were used. The first contained BfPnPDC buffer and water, and the second contained BfPnPDC buffer, 75 µM 4 and water in a total volume of 1 mL. After gentle mixing reactions were incubated at room temperature for 30 min.
The enzyme was removed from the samples using 10,000 kDa cut-off microspin columns (Microcon, Millipore). Total ionic strength adjustment buffer II solution (TISAB II) was added to the samples to a final volume of 2 mL. The fluoride ion concentration in each sample was determined.
Attempted crystallization BfPnPDC
For crystallization trials the enzyme was concentrated to 15 mg/mL in 25 mM HEPES pH 7.0, containing 0.2 mM ThDP and 0.1 mM MgCl 2 . Screening was initiated by mixing the enzyme (in the presence and absence of 4) 1:1 with the conditions of Hampton Crystal Screen II.
